Connect with us

Technology

In-Vitro Diagnostics Instruments Market size is set to grow by USD 52.9 billion from 2024-2028, Growing geriatric population boost the market, Technavio

Published

on

NEW YORK, July 31, 2024 /PRNewswire/ — The global in-vitro diagnostics instruments market size is estimated to grow by USD 52.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 9.29% during the forecast period. Growing geriatric population is driving market growth, with a trend towards potential opportunities for physician office laboratories (POL). However, strained laboratory budgets and lowering reimbursements affecting instrument sales poses a challenge. Key market players include Abbott Laboratories, Becton Dickinson and Co., Bio Rad Laboratories Inc., bioMerieux SA, Biosino Bio Technology and Science Inc, CPC Diagnostics Pvt Ltd., DAAN Gene Co. Ltd., Danaher Corp., F. Hoffmann La Roche Ltd., Guangzhou Wondfo Biotech Co. Ltd., Hologic Inc., Myriad Genetics Inc., QIAGEN NV, QuidelOrtho Corp., Shanghai Kehua Bio Engineering Co. Ltd, Shenzhen Mindray BioMedical Electronics Co. Ltd, Siemens AG, Sysmex Corp., and Thermo Fisher Scientific Inc..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

In-Vitro Diagnostics Instruments Market Scope

Report Coverage

Details

Base year

2023

Historic period

2017 – 2021

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 9.29%

Market growth 2024-2028

USD 52.9 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

8.25

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 33%

Key countries

US, Germany, China, Canada, and UK

Key companies profiled

Abbott Laboratories, Becton Dickinson and Co., Bio Rad Laboratories Inc., bioMerieux SA, Biosino Bio Technology and Science Inc, CPC Diagnostics Pvt Ltd., DAAN Gene Co. Ltd., Danaher Corp., F. Hoffmann La Roche Ltd., Guangzhou Wondfo Biotech Co. Ltd., Hologic Inc., Myriad Genetics Inc., QIAGEN NV, QuidelOrtho Corp., Shanghai Kehua Bio Engineering Co. Ltd, Shenzhen Mindray BioMedical Electronics Co. Ltd, Siemens AG, Sysmex Corp., and Thermo Fisher Scientific Inc.

 

Market Driver

In-Vitro Diagnostics (IVD) instruments market growth is driven by the increasing adoption of Point of Care (POL) testing in primary and outpatient care. POL testing, particularly in infectious disease markers, cardiovascular diseases, and diabetes care, is gaining popularity due to its convenience and quick results. Portable IVD instruments are advancing technically, enabling clinicians to perform tests in-house. The CLIA testing for molecular assays in POL practices is expected to fuel market growth. However, certain regulatory aspects regarding CLIA-waived testing may impact market expansion. Despite these challenges, the global IVD instruments market is projected to experience average growth due to the increasing trend towards POL testing. 

The In Vitro Diagnostics Instruments Market is experiencing significant growth due to the rising demand for accurate and rapid medical tests. With a focus on infectious diseases such as Malaria and Chikungunya, the market is seeing increased adoption of advanced technologies like Next-Generation Sequencing (NGS) for pathogen detection. Laboratory technicians play a crucial role in this sector, handling various samples like blood, serum, plasma, urine, saliva, and tissues. Blood banks, home care settings, pharmaceutical companies, biotechnology firms, academic institutes, and non-communicable disease segments are key end-users. Infectious diseases and chronic conditions including cardiology, gastroenterology, and cancer are major application areas. The aging population and the rise of molecular diagnostics for diseases like Alzheimer’s and various cancers further fuel market expansion. In vitro diagnostics instruments offer efficiency, accuracy, and convenience in the laboratory environment, making them an essential tool for healthcare providers. 

Discover 360° analysis of this market. For complete information, schedule your consultation – Book Here!

Market Challenges

In the In-Vitro Diagnostics Instruments Market, reimbursement policies for diagnostic testing vary across geographies and are trending downward. This puts pressure on hospitals and diagnostic laboratories to reduce expenditure on IVD instruments to maintain revenue. Workforce shortages and lost health insurance cards lead to fewer patient visits and limited testing volumes. Lean laboratories are emerging in some countries, prioritizing essential capital equipment purchases. Reduced reimbursements for certain instruments, such as SMBG in Europe and IVD instruments in the US, impact sales growth. IVD companies respond by focusing on emerging markets and adapting to market conditions. These factors are expected to restrict the growth of the global IVD Instruments Market during the forecast period.The In-Vitro Diagnostics (IVD) Instruments Market is experiencing significant growth due to advances in Next Generation Sequencing, Liquid Biopsy, and Personalized Medicine. Genetic and molecular diagnostic technologies are driving innovation in Clinical Profiles, Companion Diagnostics, and various disease areas such as Hospitals and Healthcare Facilities. IVD equipment in Immunodiagnostics, Hematology, Tissue Diagnostics, Clinical Chemistry, and Cardiac Diseases are in high demand. Challenges include Norovirus, HIV, Lyme disease, and other infectious diseases. Reagents and kits, Software and Services, and Manufacturing Technology are essential components of this market. Diabetes, Oncology, Sexually Transmitted Diseases, and Geriatric Population are key applications. Distribution channels include hypermarkets, pharmacies, drug stores, online providers, standalone laboratories, and Clinical Laboratories. Tropical diseases and Endocrine Disorders are also targeted markets. High blood cholesterol, Heart Disease, Stroke, and Chronic Conditions are significant disease areas.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This in-vitro diagnostics instruments market report extensively covers market segmentation by 

Product 1.1 Immunochemistry1.2 Clinical microbiology1.3 Molecular diagnostics1.4 OthersEnd-user 2.1 Hospitals and diagnostic laboratories2.2 Academic and research institutes2.3 Home careGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Immunochemistry- The In-Vitro Diagnostics (IVD) Instruments Market’s highly automated segment of clinical laboratories holds the largest test volume compared to others. However, the demand for immunochemistry analyzers is declining in the US and Europe due to consolidation in France, late payments from Italy, Spain, and Portugal, and reductions in expenditure in the UK, France, and Germany. In contrast, the rise of rural hospitals in China and India lacking basic diagnostics infrastructure presents a growth opportunity. Over 80 immunoassay analyzer models are available, with manufacturers responding to competition through frequent new launches or analyzer upgrades. Reduced European reimbursement is attributed to delayed spending by some medical laboratories, while the Affordable Care Act (ACA) provides greater certainty for investments. IVDs, like Ortho Clinical Diagnostics’ VITROS immunodiagnostic products for HIV-1+2 detection, aid in early COVID-19 virus detection. Roche Diagnostics received FDA approval for the first HIV-1/HIV-2 qualitative test on cobas 6800/8800 systems. Innovative products and advanced technologies continue to enter the market, intensifying competition during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

In vitro diagnostics refer to medical tests conducted outside of a living organism, using samples of bodily fluids, tissues, or other specimens. These tests play a crucial role in the detection and diagnosis of various diseases, including infectious diseases such as Zika, Malaria, and Chikungunya, as well as chronic conditions like cardiovascular diseases, cancer, and endocrine disorders. The laboratory environment is essential for the accurate and reliable performance of these tests. In vitro diagnostics are used extensively in clinical laboratories to diagnose non-communicable diseases such as heart disease, stroke, high blood cholesterol, and Alzheimer’s disease. Molecular diagnostics and pathogen detection are advanced areas of in vitro diagnostics, offering rapid and accurate results for the diagnosis of various conditions. Laboratory technicians play a vital role in the collection, preparation, and analysis of samples for in vitro diagnostic tests. In vitro diagnostics are used in various medical specialties, including cardiology, gastroenterology, and neurology, to aid in the early detection and treatment of diseases.

Market Research Overview

In Vitro Diagnostics Instruments Market: Overview The In Vitro Diagnostics Instruments Market refers to the industry that produces and supplies diagnostic tools and equipment used in medical laboratories for analyzing samples derived from bodily fluids, tissues, and other specimens. These diagnostic instruments play a crucial role in detecting various diseases, including infectious diseases such as Norovirus, HIV, Lyme disease, and Shigellosis, chronic conditions like diabetes, cardiovascular diseases, cancer, and Alzheimer’s disease, and genetic disorders. The market caters to various end-users, including hospitals, healthcare facilities, pharmacies, drug stores, online providers, standalone laboratories, and clinical laboratories. The In Vitro Diagnostics Instruments Market encompasses a wide range of diagnostic technologies, including Immunodiagnostics, Hematology, Tissue Diagnostics, Clinical Chemistry, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and others. The market is segmented into various product categories, including IVD equipment, Diagnostic Technologies, Reagents and Kits, Software and Services, and Molecular Diagnostics. Molecular Diagnostics further includes Next-Generation Sequencing (NGS), Liquid Biopsy, and Personalized Medicine. The market is also influenced by various factors such as the aging population, the rise in non-communicable diseases, and the increasing prevalence of chronic conditions. The In Vitro Diagnostics Instruments Market is driven by the growing demand for early and accurate diagnosis, the increasing focus on personalized medicine, and the increasing adoption of advanced diagnostic technologies such as NGS, liquid biopsy, and companion diagnostics. The market is also expected to witness significant growth due to the increasing prevalence of diseases such as diabetes, cancer, and cardiovascular diseases, and the growing awareness and acceptance of genetic testing. The market is highly competitive, with various players offering a wide range of diagnostic instruments and solutions. The market is also witnessing significant innovation, with new technologies and products being developed to address the evolving needs of healthcare providers and patients. Some of the key trends in the market include the increasing use of automation, the integration of artificial intelligence and machine learning, and the growing focus on point-of-care testing. The In Vitro Diagnostics Instruments Market is expected to grow at a significant CAGR during the forecast period, driven by the increasing demand for accurate and timely diagnosis, the growing prevalence of chronic diseases, and the increasing adoption of advanced diagnostic technologies. The market is also expected to be influenced by various factors such as regulatory frameworks, reimbursement policies, and technological advancements. In conclusion, the In Vitro Diagnostics Instruments Market plays a vital role in the healthcare industry by providing accurate and timely diagnosis, enabling personalized medicine, and contributing to better patient outcomes. The market is highly dynamic and is expected to witness significant growth in the coming years, driven by various factors such as the increasing prevalence of chronic diseases, the growing focus on personalized medicine, and the increasing adoption of advanced diagnostic technologies.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ProductImmunochemistryClinical MicrobiologyMolecular DiagnosticsOthersEnd-userHospitals And Diagnostic LaboratoriesAcademic And Research InstitutesHome CareGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/in-vitro-diagnostics-instruments-market-size-is-set-to-grow-by-usd-52-9-billion-from-2024-2028–growing-geriatric-population-boost-the-market-technavio-302210037.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Bloomberg Introduces Spread-to-Benchmark Quoting for EUR and GBP Portfolio Trading Baskets

Published

on

By

LONDON, June 2, 2026 /PRNewswire/ — Bloomberg today announced the launch of Spread-to-Benchmark quoting and trading for Euro (EUR) and Sterling (GBP) denominated portfolio trades through its Portfolio Trading Basket Builder (PTBB). The new functionality expands the range of quoting protocols available for European credit portfolio trading and reflects growing client demand for spread-based execution workflows, alongside increased dealer support for the convention across EUR and GBP markets.

Spread-to-Benchmark quoting is a well-established protocol for USD credit portfolio trades and is used by market participants to evaluate and execute portfolio trades. By extending this workflow to EUR and GBP portfolio trades, Bloomberg enables clients and dealers to transact using a familiar spread-based methodology across additional credit markets. 

The introduction of Spread-to-Benchmark quoting for EUR and GBP baskets reflects increased client interest in evaluating portfolio trades through a spread-based lens and the growing adoption of spread-based execution workflows in European credit markets. The workflow provides market participants with an additional framework for assessing the relationship between credit spread risk and underlying government bond yields when pricing and executing portfolio trades. 

Additional Workflow Flexibility 
The workflow complements Bloomberg’s existing portfolio trading capabilities, which support the full range of market-standard quoting conventions, including Price, Yield, Spread-to-Benchmark and Spread based workflows that reference Bloomberg’s evaluated pricing service (BVAL). This gives clients flexibility to compare and execute portfolio trades using the quoting methodology that best aligns with their investment objectives, execution preferences and internal risk management processes. 

“European credit clients continue to look for execution workflows that reflect how they evaluate risk and monitor portfolio trading outcomes,” said Harry Street, Global Head of Credit and Equities Trading Product at Bloomberg. “By expanding dealer support for Spread-to-Benchmark quoting for EUR and GBP baskets, Bloomberg is broadening the range of workflow options available to clients trading European credit portfolios.” 

“Portfolio trading workflows in fixed income continue to become more sophisticated as institutional investors look for ways to evaluate execution quality in changing market conditions,” said Kevin McPartland, Head of Market Structure & Technology Research at Crisil Coalition Greenwich. “Spread-based quoting helps market participants more clearly distinguish between the impacts of credit spread and underlying rates movements when determining how best to execute a portfolio trade.” 

Bloomberg’s Electronic Markets solutions are used by leading financial institutions to trade efficiently in over 175 markets around the world. More than 9,000 client firms use Bloomberg Electronic Markets to access industry-leading depth and breadth of liquidity across asset classes from over 800 dealers globally. Bloomberg Electronic Markets provides market participants with comprehensive solutions across the trading lifecycle, including robust price transparency, analytics, automation and execution, powered by Bloomberg’s high-quality, multi-asset class data and tools.

About Bloomberg
Bloomberg is a global leader in business and financial information, delivering trusted data, news, and insights that bring transparency, efficiency, and fairness to markets. The company helps connect influential communities across the global financial ecosystem via reliable technology solutions that enable our customers to make more informed decisions and foster better collaboration. For more information, visit Bloomberg.com/company or request a demo.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bloomberg-introduces-spread-to-benchmark-quoting-for-eur-and-gbp-portfolio-trading-baskets-302787922.html

SOURCE Bloomberg L.P.

Continue Reading

Technology

Dr. Sunho Kang, a senior battery-technology executive with leadership experience at major global battery and EV manufacturers, joins TeraWatt Technology as Head of Product and Technology

Published

on

By

SAN FRANCISCO, June 2, 2026 /PRNewswire/ — TeraWatt Technology Inc. (Headquartered in California, USA) is pleased to announce that Dr. Sunho Kang has joined the company as Head of Product and Technology.

Dr. Kang is a globally recognized battery-technology executive with more than 25 years of leadership experience spanning the United States, Asia, and Europe, and a distinguished track record of advancing innovations from laboratory research through gigafactory-scale production. He has held senior executive positions at world-leading organizations including Samsung SDI, Apple, and Volkswagen Group of America, and brings deep expertise in lithium-ion battery materials, cell engineering, and product industrialization across a broad range of applications, including electric vehicles and energy storage systems.

At TeraWatt, Dr. Kang will lead global product development and the commercialization of TeraWatt’s battery technology platform, aiming to accelerate the delivery of TeraWatt’s competitive products as well as the technology and commercialization roadmap including manufacturing scale-up.

Dr. Kang commented:

“I am thrilled to join TeraWatt Technology as Head of Product and Technology. TeraWatt’s innovative battery platform presents a tremendous opportunity to push the boundaries of lithium-ion technology, and I look forward to working with the team to accelerate product development and commercialization to deliver meaningful impact.”

TeraWatt Technology founder CEO Ken Ogata, Ph.D. commented:

“We are thrilled to welcome Dr. Kang as our Head of Product and Technology. His deep expertise in battery materials, cell engineering, and productization will be instrumental in accelerating TeraWatt’s product roadmap and technology leadership. Together with Dr. Kang, we will continue to drive our mission forward.”

About TeraWatt Technology Inc.
TeraWatt Technology Inc. is a California-based company that produces lightweight, high-power, and safe next-generation lithium-ion batteries.

Company Overview
Name: TeraWatt Technology Inc.
Representative: Co-founder and CEO Ken Ogata
Headquarters: 28 Geary St, Suite 650, San Francisco, CA 94108, United States
Founded: January 2020
Established: December 2019
URL: https://www.terawatt-technology.com/

 

View original content:https://www.prnewswire.com/news-releases/dr-sunho-kang-a-senior-battery-technology-executive-with-leadership-experience-at-major-global-battery-and-ev-manufacturers-joins-terawatt-technology-as-head-of-product-and-technology-302786854.html

SOURCE TeraWatt Technology Inc.

Continue Reading

Technology

Tencent Cloud and Soniox Announce Strategic Partnership: Combining Advanced Speech-to-Text (STT) Technology with Global Real-Time Infrastructure

Published

on

By

HONG KONG, June 2, 2026 /PRNewswire/ — Tencent Cloud, the cloud business of global technology company Tencent, today announced a strategic partnership with Soniox, a San Francisco-based speech AI company that specializes in developing high-accuracy, low-latency speech AI solutions. The collaboration integrates Soniox’s speech-to-text (STT) technology with Tencent Cloud’s Real-Time Communication (TRTC) enterprise-grade global infrastructure, enabling enterprises to build and deploy multilingual voice AI applications across 200+ countries and regions.

Elevating Enterprise Voice AI at a Global Scale

In enterprise voice AI deployments, latency directly affects user experience and application reliability. The integration of Soniox’s high-accuracy, low-latency STT with TRTC’s global transmission infrastructure reduces latency across the entire pipeline, creating a comprehensive end-to-end solution for enterprises deploying conversational AI applications worldwide.    

Soniox is the voice platform for every language. Unlike legacy speech AI, which was built primarily for English-speakers, Soniox delivers native-speaker accuracy across 60+ languages. Its technology can handle mid-sentence language switching — a user can switch between English and Chinese in a single utterance, and Soniox will capture every word with complete accuracy. All of this works through a single API that works for both speech-to-text and text-to-speech.

By integrating TRTC, the partnership leverages an enterprise-grade real-time communication backbone featuring more than 3,200 global nodes, sub-300 ms worldwide latency, and advanced capabilities such as AI noise suppression and weak-network resilience. These capabilities enable conversational AI applications to operate reliably across diverse network environments, including regions such as Southeast Asia and Africa.

With the roll out of this partnership, developers can integrate the Soniox STT API directly within the Tencent Cloud console. Whether targeting English-speaking markets or supporting languages such as Arabic, Hindi, and Malay, enterprises can build global voice applications — including intelligent customer service, voice assistants, real-time translation, and meeting transcription — to address the demands of expansion into emerging markets and multilingual scenarios.

Wison Xie, Head of Product at Tencent RTC, stated: “Tencent RTC has always been committed to providing reliable real-time communication infrastructure for global enterprises. Our partnership with Soniox brings together our strengths in enterprise-grade audio transmission and Soniox’s advanced speech recognition technology. Together, we are making it easier for businesses to deploy accurate, low-latency voice AI applications across any language and any market.”

Klemen Simonic, CEO at Soniox Inc., stated “At Soniox, our mission is to help businesses understand every word, in any language, with native speaker accuracy and exceptional speed. Partnering with Tencent Cloud combines our speech AI with world-class real-time infrastructure, enabling enterprises to build voice AI experiences that scale globally with low latency and reliability.”

About Tencent Cloud:

Tencent Cloud, one of the world’s leading cloud companies, is committed to creating innovative solutions to resolve real-world issues and enabling digital transformation for smart industries. Through our extensive global infrastructure, Tencent Cloud provides businesses across the globe with stable and secure industry-leading cloud products and services, leveraging technological advancements such as cloud computing, Big Data analytics, AI, IoT, and network security. It is our constant mission to meet the needs of industries across the board, including the fields of gaming, media and entertainment, finance, healthcare, property, retail, travel, and transportation.

About Tencent RTC:

Tencent RTC provides real-time communication solutions, including audio/video calling, live streaming, and in-game voice. With enterprise-grade security, AI-powered enhancements, and a global network of over 3,200 nodes, Tencent RTC powers mission-critical communication for customers worldwide.

About Soniox:

Soniox is a next-generation voice AI company bringing about the end of English-first speech AI. Most people on the planet did not grow up speaking English and often mix languages mid-sentence; and yet legacy speech AI was built for just English. Soniox is different: native-speaker accuracy across 60+ languages, true mid-sentence language switching, and flawless alphanumeric recognition that legacy providers still can’t match. For developers building global apps, Soniox is the only option. Try it for yourself at soniox.com.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/tencent-cloud-and-soniox-announce-strategic-partnership-combining-advanced-speech-to-text-stt-technology-with-global-real-time-infrastructure-302786832.html

SOURCE Tencent Cloud

Continue Reading

Trending